SG11201909376TA - Crystalline forms of a jak inhibitor compound - Google Patents
Crystalline forms of a jak inhibitor compoundInfo
- Publication number
- SG11201909376TA SG11201909376TA SG11201909376TA SG11201909376TA SG 11201909376T A SG11201909376T A SG 11201909376TA SG 11201909376T A SG11201909376T A SG 11201909376TA SG 11201909376T A SG11201909376T A SG 11201909376TA
- Authority
- SG
- Singapore
- Prior art keywords
- california
- international
- foster city
- hydrates
- crystalline
- Prior art date
Links
- 229940122245 Janus kinase inhibitor Drugs 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 150000004677 hydrates Chemical class 0.000 abstract 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 102220240796 rs553605556 Human genes 0.000 abstract 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 abstract 1
- SXDQRQUWNQKZBL-UHFFFAOYSA-N butanedioic acid;hydrate Chemical class O.OC(=O)CCC(O)=O SXDQRQUWNQKZBL-UHFFFAOYSA-N 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000000241 respiratory effect Effects 0.000 abstract 1
- 150000003890 succinate salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Otolaryngology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762492571P | 2017-05-01 | 2017-05-01 | |
| PCT/US2018/030144 WO2018204236A1 (en) | 2017-05-01 | 2018-04-30 | Crystalline forms of a jak inhibitor compound |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201909376TA true SG11201909376TA (en) | 2019-11-28 |
Family
ID=62165729
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201909376T SG11201909376TA (en) | 2017-05-01 | 2018-04-30 | Crystalline forms of a jak inhibitor compound |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US10251874B2 (enExample) |
| EP (1) | EP3619208B1 (enExample) |
| JP (1) | JP7096268B2 (enExample) |
| KR (1) | KR20200003121A (enExample) |
| CN (1) | CN110603255B (enExample) |
| AU (1) | AU2018261591B2 (enExample) |
| CA (1) | CA3059790A1 (enExample) |
| MX (1) | MX389014B (enExample) |
| MY (1) | MY200348A (enExample) |
| PH (1) | PH12019502425A1 (enExample) |
| SG (1) | SG11201909376TA (enExample) |
| TW (1) | TWI808083B (enExample) |
| WO (1) | WO2018204236A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017079205A1 (en) | 2015-11-03 | 2017-05-11 | Theravance Biopharma R&D Ip, Llc | Jak kinase inhibitor compounds for treatment of respiratory disease |
| JP6974487B2 (ja) | 2017-03-09 | 2021-12-01 | セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー | ４員ヘテロ環式アミドを含むｊａｋ阻害剤 |
| AR111495A1 (es) | 2017-05-01 | 2019-07-17 | Theravance Biopharma R&D Ip Llc | Compuestos de imidazo-piperidina fusionada como inhibidores de jak |
| US10406148B2 (en) | 2017-05-01 | 2019-09-10 | Theravance Biopharma R&D Ip, Llc | Methods of treatment using a JAK inhibitor compound |
| BR112021004052A2 (pt) | 2018-09-04 | 2021-05-25 | Theravance Biopharma R&D Ip, Llc | amidas de dimetil-amino azetidina como inibidores de jak |
| SG11202101751XA (en) | 2018-09-04 | 2021-03-30 | Theravance Biopharma R&D Ip Llc | 5 to 7 membered heterocyclic amides as jak inhibitors |
| WO2020051135A1 (en) | 2018-09-04 | 2020-03-12 | Theravance Biopharma R&D Ip, Llc | Process for preparing jak inhibitors and intermediates thereof |
| MX2021004582A (es) | 2018-10-29 | 2021-06-15 | Theravance Biopharma R&D Ip Llc | Compuesto 2-azabiciclo hexano inhibidor de jak. |
| TW202144343A (zh) * | 2020-03-02 | 2021-12-01 | 美商施萬生物製藥研發 Ip有限責任公司 | Jak抑制劑化合物之結晶水合物 |
| CN117083273A (zh) * | 2021-03-26 | 2023-11-17 | 施万生物制药研发Ip有限责任公司 | Jak抑制剂化合物的二盐酸盐的晶型 |
| TW202317550A (zh) | 2021-06-25 | 2023-05-01 | 美商施萬生物製藥研發 Ip有限責任公司 | 作為jak抑制劑之咪唑吲唑化合物 |
| PE20241589A1 (es) * | 2021-12-17 | 2024-08-01 | Daewoong Pharmaceutical Co Ltd | Nueva sal de adicion de acido y ofrma cristalina de (2r,3s)-2-(3-(4,5-dicloro-1h-benzo[d]imidazol-1-il)propil)piperidin-3-ol |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI262914B (en) | 1999-07-02 | 2006-10-01 | Agouron Pharma | Compounds and pharmaceutical compositions for inhibiting protein kinases |
| US7872014B2 (en) | 2003-07-23 | 2011-01-18 | Exelixis, Inc. | Anaplastic lymphoma kinase modulators and methods of use |
| US20050090529A1 (en) | 2003-07-31 | 2005-04-28 | Pfizer Inc | 3,5 Disubstituted indazole compounds with nitrogen-bearing 5-membered heterocycles, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation |
| US7884109B2 (en) | 2005-04-05 | 2011-02-08 | Wyeth Llc | Purine and imidazopyridine derivatives for immunosuppression |
| US8648069B2 (en) | 2007-06-08 | 2014-02-11 | Abbvie Inc. | 5-substituted indazoles as kinase inhibitors |
| JP2010111624A (ja) | 2008-11-06 | 2010-05-20 | Shionogi & Co Ltd | Ｔｔｋ阻害作用を有するインダゾール誘導体 |
| US20120029190A1 (en) | 2009-04-03 | 2012-02-02 | Douglas Burdi | Compounds for treating disorders mediated by metabotropic glutamate receptor 5, and methods of use thereof |
| LT3001903T (lt) | 2009-12-21 | 2018-01-10 | Samumed, Llc | 1h-pirazolo[3,4-b]piridinai ir jų terapinis panaudojimas |
| US8575336B2 (en) | 2011-07-27 | 2013-11-05 | Pfizer Limited | Indazoles |
| MD4649C1 (ro) | 2013-12-05 | 2020-04-30 | Pfizer Inc. | Pirol[2,3-d]pirimidinil, pirol[2,3-b]pirazinil şi pirol[2,3-d]piridinil acrilamide |
| PE20161475A1 (es) | 2014-05-14 | 2017-01-08 | Pfizer | Pirazolopiridinas y pirazolopirimidinas |
| WO2016026078A1 (en) | 2014-08-19 | 2016-02-25 | Changzhou Jiekai Pharmatech Co., Ltd. | Heterocyclic compounds as erk inhibitors |
| KR101663277B1 (ko) | 2015-03-30 | 2016-10-06 | 주식회사 녹십자 | TNIK, IKKε 및 TBK1 억제제로서의 피라졸계 유도체 및 이를 포함하는 약학적 조성물 |
| WO2017077288A1 (en) | 2015-11-03 | 2017-05-11 | Topivert Pharma Limited | 4,5,6,7-tetrahydro-1h-imidazo[4,5-c]pyridine and 1,4,5,6,7,8-hexahydroimidazo[4,5-d]azepine derivatives as janus kinase inhibitors |
| EP3712152B1 (en) | 2015-11-03 | 2021-01-13 | Topivert Pharma Limited | 4,5,6,7-tetrahydro-1h-imidazo[4,5-c]pyridine and 1,4,5,6,7,8-hexahydroimidazo[4,5-d]azepine derivatives as janus kinase inhibitors |
| WO2017079205A1 (en) | 2015-11-03 | 2017-05-11 | Theravance Biopharma R&D Ip, Llc | Jak kinase inhibitor compounds for treatment of respiratory disease |
-
2018
- 2018-04-30 TW TW107114723A patent/TWI808083B/zh not_active IP Right Cessation
- 2018-04-30 JP JP2019559304A patent/JP7096268B2/ja active Active
- 2018-04-30 EP EP18724753.1A patent/EP3619208B1/en active Active
- 2018-04-30 SG SG11201909376T patent/SG11201909376TA/en unknown
- 2018-04-30 US US15/966,452 patent/US10251874B2/en active Active
- 2018-04-30 AU AU2018261591A patent/AU2018261591B2/en not_active Ceased
- 2018-04-30 WO PCT/US2018/030144 patent/WO2018204236A1/en not_active Ceased
- 2018-04-30 CN CN201880029410.5A patent/CN110603255B/zh not_active Expired - Fee Related
- 2018-04-30 MX MX2019012945A patent/MX389014B/es unknown
- 2018-04-30 CA CA3059790A patent/CA3059790A1/en active Pending
- 2018-04-30 KR KR1020197035428A patent/KR20200003121A/ko not_active Abandoned
- 2018-04-30 MY MYPI2019005859A patent/MY200348A/en unknown
-
2019
- 2019-10-25 PH PH12019502425A patent/PH12019502425A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2018204236A1 (en) | 2018-11-08 |
| MY200348A (en) | 2023-12-21 |
| KR20200003121A (ko) | 2020-01-08 |
| EP3619208C0 (en) | 2023-06-07 |
| CA3059790A1 (en) | 2018-11-08 |
| RU2019138700A (ru) | 2021-06-02 |
| AU2018261591B2 (en) | 2021-09-02 |
| TWI808083B (zh) | 2023-07-11 |
| CN110603255B (zh) | 2023-02-10 |
| TW201900643A (zh) | 2019-01-01 |
| US20180311223A1 (en) | 2018-11-01 |
| MX389014B (es) | 2025-03-20 |
| CN110603255A (zh) | 2019-12-20 |
| EP3619208B1 (en) | 2023-06-07 |
| EP3619208A1 (en) | 2020-03-11 |
| PH12019502425A1 (en) | 2020-06-29 |
| MX2019012945A (es) | 2019-12-16 |
| AU2018261591A1 (en) | 2019-11-07 |
| JP7096268B2 (ja) | 2022-07-05 |
| RU2019138700A3 (enExample) | 2022-01-26 |
| US10251874B2 (en) | 2019-04-09 |
| JP2020518582A (ja) | 2020-06-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201909376TA (en) | Crystalline forms of a jak inhibitor compound | |
| SG11201908604YA (en) | Fused imidazo-piperidine jak inhibitor compound | |
| SG11201909019SA (en) | Methods of treatment using a jak inhibitor compound | |
| SG11201907840RA (en) | Fused imidazo-piperidine jak inhibitors | |
| SG11201810983PA (en) | Novel heterocyclic derivatives useful as shp2 inhibitors | |
| SG11201808708RA (en) | Heterocyclic amides useful as protein modulators | |
| SG11201907356SA (en) | Piperidine-substituted mnk inhibitors and methods related thereto | |
| SG11201804934PA (en) | Novel Compounds | |
| SG11201809714TA (en) | Piperidines as menin inhibitors | |
| SG11201807301SA (en) | Spiro-condensed pyrrolidine derivatives as deubiquitylating enzymes (dub) inhibitors | |
| SG11201804132UA (en) | Eif4-a-inhibiting compounds and methods related thereto | |
| SG11201808990QA (en) | Compositions for topical application of compounds | |
| SG11201909278SA (en) | Fungicidal oxadiazoles | |
| SG11201909949XA (en) | Targeted immunotolerance | |
| SG11201908820VA (en) | Novel heterocyclic derivatives useful as shp2 inhibitors | |
| SG11201805300QA (en) | Heterocyclic compounds as immunomodulators | |
| SG11201805645QA (en) | Lsd1 inhibitors | |
| SG11201907023UA (en) | Method of reducing neutropenia | |
| SG11201806863WA (en) | Tetracyclic pyridone compounds as antivirals | |
| SG11201809344QA (en) | Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde | |
| SG11201804294WA (en) | Tank-binding kinase inhibitor compounds | |
| SG11201408094YA (en) | Neprilysin inhibitors | |
| SG11201805709RA (en) | Anti-pro/latent myostatin antibodies and methods of use thereof | |
| SG11201906163TA (en) | Nucleotide hemi-sulfate salt for the treatment of hepatitis c virus | |
| SG11201909155VA (en) | Ask1 inhibitor compounds and uses thereof |